- call +1-201-465-4211
- email sales@mrinsights.biz
An orphan disease is defined as a condition that affects fewer than 200,000 people nationwide. This includes diseases as familiar as cystic fibrosis, Lou Gehrig's disease, and Tourette's syndrome, and as unfamiliar as Hamburger disease, Job syndrome, and acromegaly, or "gigantism." Some diseases have patient populations of fewer than a hundred.
Scope of the Report:
This report studies the Orphan Diseases market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Orphan Diseases market by product type and applications/end industries.
New rare diseases are discovered every year. Most are inherited and caused by alterations or defects in genes (mutations). Others can be acquired as a result of environmental and toxic conditions. Genes are pieces of DNA, part of the code that determines the traits and individual characteristics of all living things.
The global Orphan Diseases market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Orphan Diseases.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Bristol-Myers Squibb
Novartis
Celgene
Roche
Pfizer
Alexion
Sanofi
Vertex Pharmaceuticals
GlaxoSmithKline
Merck
Abbvie
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Autoimmune Disorders
Genetic Disorders
Blood Disorders
Cancer
Growth Disorder
Cardiovascular Diseases
Neurological Disorders
Respiratory Disorders
Digestive Disorders
Eye Disorders
Market Segment by Applications, can be divided into
Hospitals And Clinics
Research Laboratories
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Orphan Diseases Market Overview
1.1 Product Overview and Scope of Orphan Diseases
1.2 Classification of Orphan Diseases by Types
1.2.1 Global Orphan Diseases Revenue Comparison by Types (2017-2023)
1.2.2 Global Orphan Diseases Revenue Market Share by Types in 2017
1.2.3 Autoimmune Disorders
1.2.4 Genetic Disorders
1.2.5 Blood Disorders
1.2.6 Cancer
1.2.7 Growth Disorder
1.2.8 Cardiovascular Diseases
1.2.9 Neurological Disorders
1.2.10 Respiratory Disorders
1.2.11 Digestive Disorders
1.2.12 Eye Disorders
1.3 Global Orphan Diseases Market by Application
1.3.1 Global Orphan Diseases Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals And Clinics
1.3.3 Research Laboratories
1.4 Global Orphan Diseases Market by Regions
1.4.1 Global Orphan Diseases Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Orphan Diseases Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Orphan Diseases Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Orphan Diseases Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Orphan Diseases Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Orphan Diseases Status and Prospect (2013-2023)
1.5 Global Market Size of Orphan Diseases (2013-2023)
2 Manufacturers Profiles
2.1 Bristol-Myers Squibb
2.1.1 Business Overview
2.1.2 Orphan Diseases Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Bristol-Myers Squibb Orphan Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.2 Novartis
2.2.1 Business Overview
2.2.2 Orphan Diseases Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novartis Orphan Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.3 Celgene
2.3.1 Business Overview
2.3.2 Orphan Diseases Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Celgene Orphan Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.4 Roche
2.4.1 Business Overview
2.4.2 Orphan Diseases Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Roche Orphan Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.5 Pfizer
2.5.1 Business Overview
2.5.2 Orphan Diseases Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Pfizer Orphan Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.6 Alexion
2.6.1 Business Overview
2.6.2 Orphan Diseases Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Alexion Orphan Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.7 Sanofi
2.7.1 Business Overview
2.7.2 Orphan Diseases Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Sanofi Orphan Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.8 Vertex Pharmaceuticals
2.8.1 Business Overview
2.8.2 Orphan Diseases Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Vertex Pharmaceuticals Orphan Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.9 GlaxoSmithKline
2.9.1 Business Overview
2.9.2 Orphan Diseases Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 GlaxoSmithKline Orphan Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.10 Merck
2.10.1 Business Overview
2.10.2 Orphan Diseases Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Merck Orphan Diseases Revenue, Gross Margin and Market Share (2016-2017)
2.11 Abbvie
2.11.1 Business Overview
2.11.2 Orphan Diseases Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Abbvie Orphan Diseases Revenue, Gross Margin and Market Share (2016-2017)
3 Global Orphan Diseases Market Competition, by Players
3.1 Global Orphan Diseases Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Orphan Diseases Players Market Share
3.2.2 Top 10 Orphan Diseases Players Market Share
3.3 Market Competition Trend
4 Global Orphan Diseases Market Size by Regions
4.1 Global Orphan Diseases Revenue and Market Share by Regions
4.2 North America Orphan Diseases Revenue and Growth Rate (2013-2018)
4.3 Europe Orphan Diseases Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Orphan Diseases Revenue and Growth Rate (2013-2018)
4.5 South America Orphan Diseases Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Orphan Diseases Revenue and Growth Rate (2013-2018)
5 North America Orphan Diseases Revenue by Countries
5.1 North America Orphan Diseases Revenue by Countries (2013-2018)
5.2 USA Orphan Diseases Revenue and Growth Rate (2013-2018)
5.3 Canada Orphan Diseases Revenue and Growth Rate (2013-2018)
5.4 Mexico Orphan Diseases Revenue and Growth Rate (2013-2018)
6 Europe Orphan Diseases Revenue by Countries
6.1 Europe Orphan Diseases Revenue by Countries (2013-2018)
6.2 Germany Orphan Diseases Revenue and Growth Rate (2013-2018)
6.3 UK Orphan Diseases Revenue and Growth Rate (2013-2018)
6.4 France Orphan Diseases Revenue and Growth Rate (2013-2018)
6.5 Russia Orphan Diseases Revenue and Growth Rate (2013-2018)
6.6 Italy Orphan Diseases Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Orphan Diseases Revenue by Countries
7.1 Asia-Pacific Orphan Diseases Revenue by Countries (2013-2018)
7.2 China Orphan Diseases Revenue and Growth Rate (2013-2018)
7.3 Japan Orphan Diseases Revenue and Growth Rate (2013-2018)
7.4 Korea Orphan Diseases Revenue and Growth Rate (2013-2018)
7.5 India Orphan Diseases Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Orphan Diseases Revenue and Growth Rate (2013-2018)
8 South America Orphan Diseases Revenue by Countries
8.1 South America Orphan Diseases Revenue by Countries (2013-2018)
8.2 Brazil Orphan Diseases Revenue and Growth Rate (2013-2018)
8.3 Argentina Orphan Diseases Revenue and Growth Rate (2013-2018)
8.4 Colombia Orphan Diseases Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Orphan Diseases by Countries
9.1 Middle East and Africa Orphan Diseases Revenue by Countries (2013-2018)
9.2 Saudi Arabia Orphan Diseases Revenue and Growth Rate (2013-2018)
9.3 UAE Orphan Diseases Revenue and Growth Rate (2013-2018)
9.4 Egypt Orphan Diseases Revenue and Growth Rate (2013-2018)
9.5 Nigeria Orphan Diseases Revenue and Growth Rate (2013-2018)
9.6 South Africa Orphan Diseases Revenue and Growth Rate (2013-2018)
10 Global Orphan Diseases Market Segment by Type
10.1 Global Orphan Diseases Revenue and Market Share by Type (2013-2018)
10.2 Global Orphan Diseases Market Forecast by Type (2018-2023)
10.3 Autoimmune Disorders Revenue Growth Rate (2013-2023)
10.4 Genetic Disorders Revenue Growth Rate (2013-2023)
10.5 Blood Disorders Revenue Growth Rate (2013-2023)
10.6 Cancer Revenue Growth Rate (2013-2023)
10.7 Growth Disorder Revenue Growth Rate (2013-2023)
10.8 Cardiovascular Diseases Revenue Growth Rate (2013-2023)
10.9 Neurological Disorders Revenue Growth Rate (2013-2023)
10.10 Respiratory Disorders Revenue Growth Rate (2013-2023)
10.11 Digestive Disorders Revenue Growth Rate (2013-2023)
10.12 Eye Disorders Revenue Growth Rate (2013-2023)
11 Global Orphan Diseases Market Segment by Application
11.1 Global Orphan Diseases Revenue Market Share by Application (2013-2018)
11.2 Orphan Diseases Market Forecast by Application (2018-2023)
11.3 Hospitals And Clinics Revenue Growth (2013-2018)
11.4 Research Laboratories Revenue Growth (2013-2018)
12 Global Orphan Diseases Market Size Forecast (2018-2023)
12.1 Global Orphan Diseases Market Size Forecast (2018-2023)
12.2 Global Orphan Diseases Market Forecast by Regions (2018-2023)
12.3 North America Orphan Diseases Revenue Market Forecast (2018-2023)
12.4 Europe Orphan Diseases Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Orphan Diseases Revenue Market Forecast (2018-2023)
12.6 South America Orphan Diseases Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Orphan Diseases Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Orphan Diseases Picture
Table Product Specifications of Orphan Diseases
Table Global Orphan Diseases and Revenue (Million USD) Market Split by Product Type
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
